Search results for "antagonist"

showing 10 items of 1660 documents

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Nov…

2017

Abstract Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide. Darolutamide significantly inhibited cell growth and AR transcriptional activity in enzalutamide-resistant MR49F cells in vitro, and led to decreased tumor volume and serum prostate-specific antigen l…

0301 basic medicineMaleModels MolecularTime FactorsTranscription GeneticProtein ConformationProstate cancerchemistry.chemical_compoundMice0302 clinical medicineMolecular Targeted TherapyTumor BurdenDarolutamideReceptors Androgen030220 oncology & carcinogenesisBenzamidesmedicine.drugSignal Transductionmedicine.medical_specialtyBicalutamideUrologyPartial agonist03 medical and health sciencesStructure-Activity RelationshipIn vivoInternal medicineCell Line TumorNitrilesPhenylthiohydantoinmedicineAndrogen Receptor AntagonistsEnzalutamideAnimalsHumansCell ProliferationDose-Response Relationship DrugCell growthbusiness.industryProstatic Neoplasmsmedicine.diseaseXenograft Model Antitumor AssaysAndrogen receptor030104 developmental biologyEndocrinologychemistryDrug Resistance NeoplasmMutationCancer researchPyrazolesbusinessEuropean urology
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer

2019

Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may prospectively decrease absolute lean mass (LM) and increase absolute fat mass (FM). Given that estimates of LM by dual‐energy X‐ray absorptiometry may be overestimated in obese people, this study examined the influence of adiposity on muscle health in men treated with ADT for PCa. Methods: This cross‐sectional study examined the influence of adiposity on total and appendicular LM (ALM), muscle cross‐sectional (CSA), and muscle strength in 70 men treated with ADT [mean (standard deviation) age, 71 (6) years] for PCa compared with age‐matched PCa (n = 52) and healthy controls (n = 70). Total body LM, FM and ALM, and …

0301 basic medicineMaleSarcopenialcsh:Diseases of the musculoskeletal systemBody compositionprostatic neoplasmsBody Mass IndexAndrogen deprivation therapyProstate cancer0302 clinical medicineAbsorptiometry PhotonMedicineOrthopedics and Sports MedicineQuantitative computed tomographyAdipositymedicine.diagnostic_testeturauhassyöpäOrgan Sizelcsh:Human anatomyMiddle Agedadipose tissue030220 oncology & carcinogenesissyöpätauditOriginal ArticleProstatic neoplasmsmedicine.medical_specialtymedicine.drug_classUrologyrasvakudoksetAdipose tissuelcsh:QM1-695sarcopenia03 medical and health sciencesAtrophyPhysiology (medical)HumansMuscle SkeletalatrofiakehonkoostumusAgedbusiness.industryAndrogen AntagonistsOriginal Articlesmedicine.diseaseAndrogen030104 developmental biologyCross-Sectional StudiesSarcopeniaLean body massAtrophylcsh:RC925-935businessBody mass indexlihassurkastumasairaudetBiomarkersJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression

2017

The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome (ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly understood. Arterial thrombosis is the key event in ACS; however, direct vascular effects of either ticagrelor or clopidogrel with focus on arterial thrombosis and its key trigger tissue factor have not been previously investigated.Methods and results: Human aortic endothelial cells were treated with ticagrelor or clopidogrel active metabolite (CAM) and stimulated with tumour necrosis factor-alpha (TNF-α); effects on procoagulant tissue factor (TF) expression and activity, its counter-player TF pathway inhibito…

0301 basic medicineMaleTicagrelorAdenosineTime FactorsPhysiology030204 cardiovascular system & hematology2737 Physiology (medical)0302 clinical medicineP2Y12AntithromboticCells CulturedClopidogrelReceptors Purinergic P2Y123. Good healthClopidogrelmedicine.anatomical_structureCoagulation10209 Clinic for CardiologyCardiologyCardiology and Cardiovascular MedicineTicagrelormedicine.drugBlood PlateletsAcute coronary syndromemedicine.medical_specialtyProteasome Endopeptidase ComplexTiclopidineEndotheliumDown-Regulation610 Medicine & health2705 Cardiology and Cardiovascular MedicineThromboplastinEquilibrative Nucleoside Transporter 103 medical and health sciencesTissue factorFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineAnimalsHumanscardiovascular diseasesBlood Coagulationbusiness.industryTumor Necrosis Factor-alphaEndothelial CellsThrombosis1314 Physiologymedicine.diseaseMice Inbred C57BLDisease Models Animal030104 developmental biologyProteolysisPurinergic P2Y Receptor AntagonistsbusinessCarotid Artery InjuriesPlatelet Aggregation Inhibitors
researchProduct

Differential Impact of Ad Libitum or Intermittent High-Fat Diets on Bingeing Ethanol-Mediated Behaviors

2019

Background: Dietary factors have significant effects on the brain, modulating mood, anxiety, motivation and cognition. To date, no attention has been paid to the consequences that the combination of ethanol (EtOH) and a high-fat diet (HFD) have on learning and mood disorders during adolescence. The aim of the present work was to evaluate the biochemical and behavioral consequences of ethanol binge drinking and an HFD consumption in adolescent mice. Methods: Animals received either a standard diet or an HFD (ad libitum vs. binge pattern) in combination with ethanol binge drinking and were evaluated in anxiety and memory. The metabolic profile and gene expression of leptin receptors and clock…

0301 basic medicineMalecognitionHippocampusCLOCK ProteinsWhite adipose tissueWeight GainHippocampusMice0302 clinical medicineBulimiaPrefrontal cortexAdiposityNutrition and DieteticsLeptindigestive oral and skin physiologyARNTL Transcription Factorsfood and beveragesanxietyhigh-fat dietReceptors Leptinlcsh:Nutrition. Foods and food supplyhormones hormone substitutes and hormone antagonistsmedicine.medical_specialtymedicine.drug_classBinge drinkingPrefrontal Cortexlcsh:TX341-641Diet High-FatAnxiolyticleptinArticle03 medical and health sciencesInternal medicinemedicineAnimalsLearningLeptin receptorEthanolbusiness.industryMood Disordersnutritional and metabolic diseasesmedicine.diseasebinge drinking030104 developmental biologyEndocrinologyMood disordersgene expressionbusiness030217 neurology & neurosurgeryFood Science
researchProduct

Angiotensin II type II receptors and colonic dysmotility in 2,4-dinitrofluorobenzenesulfonic acid-induced colitis in rats

2016

Background: Angiotensin II (Ang II), the main peptide of the renin-angiotensin system (RAS), has been suggested to be involved in inflammatory bowel diseases. Since RAS has emerged as gut motility regulator, and dysmotility is associated with intestinal inflammation, our objective was to investigate in rat 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis the functionality of RAS and its contribution to colonic motor alterations. Methods: The effects of Ang II on the longitudinal colonic muscular contractility of control and DNBS-treated rats were characterized in vitro. Transcripts encoding for Ang II receptors were investigated by RT-PCR. Key Results: Inflamed preparations showed a l…

0301 basic medicineMalemedicine.medical_specialtyAngiotensin receptormedicine.drug_classColonPhysiologyInflammationAT2 receptorReceptor Angiotensin Type 2Bowel inflammationEndocrine and Autonomic SystemContractilityRenin-Angiotensin System03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsRats WistarReceptorAngiotensin II receptor type 1Endocrine and Autonomic SystemsChemistryAT1 receptorAngiotensin IIMuscle contractilityGastroenterologyMuscle SmoothNitric oxideReceptor antagonistColitisAngiotensin II030104 developmental biologyEndocrinologyLosartancardiovascular system030211 gastroenterology & hepatologyDinitrofluorobenzenemedicine.symptomGastrointestinal Motilityhormones hormone substitutes and hormone antagonistsmedicine.drugMuscle Contraction
researchProduct

Dopaminergic-GABAergic interplay and alcohol binge drinking

2019

© 2019 Elsevier Ltd The dopamine D 3 receptor (D 3 R), in the nucleus accumbens (NAc), plays an important role in alcohol reward mechanisms. The major neuronal type within the NAc is the GABAergic medium spiny neuron (MSN), whose activity is regulated by dopaminergic inputs. We previously reported that genetic deletion or pharmacological blockade of D 3 R increases GABA A α6 subunit in the ventral striatum. Here we tested the hypothesis that D 3 R-dependent changes in GABA A α6 subunit in the NAc affect voluntary alcohol intake, by influencing the inhibitory transmission of MSNs. We performed in vivo and ex vivo experiments in D 3 R knockout (D 3 R −/− ) mice and wild type littermates (D 3 …

0301 basic medicineMalemedicine.medical_specialtyDopaminergic-GABAergicSettore BIO/09 - FISIOLOGIAAlpha6 subunit; Dopamine D3 receptor; Ethanol; Furosemide (PubChem CID: 3440); GABA(A)receptor; Nucleus accumbens; Ro 15-4513; Ro 15-4513 (PubChem CID: 5081); SB 277011A (PubChem CID: 75358288)Alpha6 subunitNucleus accumbensMedium spiny neuronInhibitory postsynaptic potentialNucleus AccumbensBinge Drinking03 medical and health sciencesMiceDopamine D3 receptor0302 clinical medicineDopamine receptor D3Internal medicinemedicineAnimalsFurosemide (PubChem CID: 3440)Nucleus accumbenPharmacology & PharmacyRNA MessengerRo 15-4513GABAergic NeuronsSB 277011A (PubChem CID: 75358288).PharmacologyMice KnockoutEthanolGABAA receptorChemistryDopaminergicAntagonistReceptors Dopamine D3Receptors GABA-ARo 15-4513 (PubChem CID: 5081)GABA(A)receptor3. Good healthProtein Subunits030104 developmental biologyEndocrinologynervous systemGene Expression Regulation030220 oncology & carcinogenesisGABAergicNucleus accumbensSB 277011A (PubChem CID: 75358288)
researchProduct

Mechanisms involved in the increased sensitivity of the rabbit basilar artery to atrial natriuretic peptide in diabetes.

2017

Atrial natriuretic peptide (ANP) is a vasodilator with significant regional differences and controversial effects in the cerebral circulation, a vascular bed particularly prone to diabetes-induced complications. The present study has investigated how alloxan-induced diabetes modifies the mechanisms involved in the response of the rabbit basilar artery to ANP. ANP (10(-12) -10(-7) M) relaxed precontracted basilar arteries, with higher potency in diabetic than in control rabbits. In arteries from both groups of animals, endothelium removal reduced ANP-induced relaxations. Inhibition of NO-synthesis attenuated ANP-induced relaxation but this attenuation was lower in diabetic than in control ra…

0301 basic medicineMalemedicine.medical_specialtyEndotheliummedicine.drug_classRabbit basilar arteryVasodilationProstanoidsNitric OxidePotassium channelsDiabetes Mellitus ExperimentalGlibenclamide03 medical and health sciencesCerebral circulationAtrial natriuretic peptidemedicine.arteryInternal medicinemedicineBasilar arteryNatriuretic peptideAnimalsAtrial natriuretic peptidePharmacologyDose-Response Relationship Drugbusiness.industryDiabetesNitric oxideIberiotoxin030104 developmental biologyEndocrinologymedicine.anatomical_structureBasilar Arterycardiovascular systemProstaglandinsRabbitsbusinessReceptors Atrial Natriuretic Factorhormones hormone substitutes and hormone antagonistsAtrial Natriuretic Factormedicine.drugEuropean journal of pharmacology
researchProduct

Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation.

2017

The Mas receptor is involved in the angiotensin (Ang)-(1-7) vasodilatory actions by increasing nitric oxide production (NO). We have previously demonstrated an increased production of Ang-(1-7) in human umbilical vein endothelial cells (HUVEC) exposed to estradiol (E2), suggesting a potential cross-talk between E2 and the Ang-(1-7)/Mas receptor axis. Here, we explored whether the vasoactive response and NO-related signalling exerted by E2 are influenced by Mas. HUVEC were exposed to 10nM E2 for 24h in the presence or absence of the selective Mas receptor antagonist A779, and the estrogen receptor (ER) antagonist ICI182780 (ICI). E2 increased Akt and endothelial nitric oxide synthase (eNOS) …

0301 basic medicineMalemedicine.medical_specialtyEstrogen receptorVasodilationNitric OxideBiochemistryProto-Oncogene MasUmbilical veinNitric oxideReceptors G-Protein-Coupled03 medical and health scienceschemistry.chemical_compoundMiceEnosInternal medicineProto-Oncogene ProteinsmedicineHuman Umbilical Vein Endothelial CellsAnimalsHumansProtein kinase BPharmacologybiologyAntagonistbiology.organism_classificationMice Inbred C57BLVasodilation030104 developmental biologyEndocrinologychemistryReceptors EstrogenMyographBiochemical pharmacology
researchProduct

Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain.

2018

Growing evidence suggests a link between obesity and neurodegeneration. The purpose of the present study was to explore the neuroprotective potential of glucagon-like peptide-2 (GLP-2) in the brain of high fat diet (HFD)-fed mice. Markers of inflammation and oxidative stress were analysed in the brains of obese mice chronically treated with [Gly2]-GLP-2 (teduglutide), the stable analogue of the GLP-2, and they were compared to age-matched untreated obese and lean animals. Neurodegeneration was examined by TUNEL assay. HFD feeding increased the expression of pro-inflammatory mediators (NF-kB, IL-8, TNF-α, IL-1β and IL-6), glial fibrillary acidic protein (GFAP), index of gliosis and neurodege…

0301 basic medicineMalemedicine.medical_specialtyInflammationmedicine.disease_causeDiet High-FatSettore BIO/09 - FisiologiaNeuroprotectionlcsh:RC321-57103 medical and health sciences0302 clinical medicineNeuroinflammationInternal medicinemedicineGlucagon-Like Peptide 2AnimalsObesityNeurodegenerationlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroinflammationTUNEL assayGlial fibrillary acidic proteinbiologyChemistryNeurodegenerationdigestive oral and skin physiologyBrainmedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyNeuroprotective AgentsNeurologyGliosisOxidative stressAstrocytesbiology.proteinGlucagon-Like Peptide-2 ReceptorOxidative streEncephalitismedicine.symptomInflammation MediatorsGLP-2030217 neurology & neurosurgeryOxidative stresshormones hormone substitutes and hormone antagonistsNeurobiology of disease
researchProduct